An Open Label Follow-On Study of Safety and Pharmacodynamic Effects of 24 Weeks of Treatment With DIO-902 in Combination With Metformin and Atorvastatin in Subjects With Type 2 Diabetes Mellitus (Protocol No. DIO-503)

Trial Profile

An Open Label Follow-On Study of Safety and Pharmacodynamic Effects of 24 Weeks of Treatment With DIO-902 in Combination With Metformin and Atorvastatin in Subjects With Type 2 Diabetes Mellitus (Protocol No. DIO-503)

Recruiting
Phase of Trial: Phase II/III

Latest Information Update: 12 Mar 2008

At a glance

  • Drugs Atorvastatin; DIO 902
  • Indications Lipid metabolism disorders; Type 2 diabetes mellitus
  • Focus Pharmacodynamics
  • Sponsors DiObex
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 12 Mar 2008 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top